Cancer vaccines

Global Peptide Cancer Vaccine Market Clinical Trials Research Outlook 2026

Retrieved on: 
Thursday, April 22, 2021
Medicine, Clinical medicine, Vaccines, Medical specialties, Vaccination, Vaccine, Virology, Cancer vaccines, Peptide vaccine, Medical research, Tumor antigen vaccine, Gp100:209-217

b'"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" Report Highlights:\nGlobal Peptide Cancer Drugs Market Opportunity: >USD 20 Billion\nGlobal Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase\nNumber Of Peptide Vaccines In Pipeline: >90\n"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" provides comprehensive insight on clinical and non-clinical factors that are driving the global Peptide Cancer Vaccine market and its impact on the global pharmaceutical market landscape.

Key Points: 
  • b'"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" Report Highlights:\nGlobal Peptide Cancer Drugs Market Opportunity: >USD 20 Billion\nGlobal Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase\nNumber Of Peptide Vaccines In Pipeline: >90\n"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" provides comprehensive insight on clinical and non-clinical factors that are driving the global Peptide Cancer Vaccine market and its impact on the global pharmaceutical market landscape.
  • Currently, GV10001 is the only peptide based vaccine approved in Korea for the management of pancreatic cancer.
  • The high growth rate is mainly attributed to the high prevalence of cancer, robust clinical pipeline of vaccines and the safety and cost-efficacy of peptide based vaccines.\nIn terms of geography, it is expected that North America will dominate the global peptide cancer vaccine market landscape after the commercial launch of first peptide cancer vaccine in the region.
  • In coming years, the market will witness rapid approval of several peptide based cancer vaccines which will boost the growth of market.

Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer

Retrieved on: 
Monday, April 5, 2021
Histopathology, Prostate cancer, Cancer, Clinical medicine, Causes of death, Cancer vaccines

The study, expected to begin in Q2 2021, will be the first clinical evaluation of ADXS-504, Advaxis off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.

Key Points: 
  • The study, expected to begin in Q2 2021, will be the first clinical evaluation of ADXS-504, Advaxis off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.
  • Mark Stein, M.D., associate professor of medicine in the Division of Hematology/Oncology at Columbia University Vagelos College of Physicians and Surgeons, will be the studys principal investigator.
  • The study will also evaluate preliminary clinical and immune responses following treatment with ADXS-504 monotherapy.
  • Nearly 248,530 men in the United States will be diagnosed with prostate cancer in 2021, and approximately 34,130 will die from this disease.

New Study from Qualtrics Reveals a Majority of Employees Support Vaccine Mandates

Retrieved on: 
Wednesday, March 31, 2021
Medical specialties, Vaccination, Vaccine, Virology, Clinical medicine, Medicine, Pharmaceuticals policy, Cancer vaccines, Vaccines, Vaccine hesitancy

1 Experience Management (XM) Platform and creator of the XM category, today released a new study that examines customers' and employees' attitudes toward vaccine mandates.

Key Points: 
  • 1 Experience Management (XM) Platform and creator of the XM category, today released a new study that examines customers' and employees' attitudes toward vaccine mandates.
  • The study reveals that employees largely support vaccine mandates, with a large number of them saying they will wait to be vaccinated before returning to the office.
  • Customers are also more likely to support businesses that require their employees to be vaccinated.
  • "Our study found that two out of three workers say they would support vaccine mandates, while more than half say they are more likely to support companies that require employees to be vaccinated.

ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer

Retrieved on: 
Monday, March 29, 2021
Research, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Clinical medicine, Cancer treatments, Medicine, Virotherapy, MCRPC, Prostate cancer, Cancer vaccines, Cancer immunotherapy, Immunotherapy, Adenoviridae, Prostvac, James L. Gulley

( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced the publication of Phase I data in The Journal of ImmunoTherapy of Cancer (JITC).

Key Points: 
  • ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced the publication of Phase I data in The Journal of ImmunoTherapy of Cancer (JITC).
  • The publication, titled Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/ brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) highlighted the safety, T-cell immunogenicity, and clinical activity of ImmunityBios second-generation human adenovirus (hAd5) in patients with incurable mCRPC.
  • These early results, which include signals of clinical activity and durable stable disease, are encouraging for patients with highly resistant advanced metastatic prostate cancer and warrants further study.
  • Importantly, these hAd5-based vaccines have shown an ability to overcome previous adenovirus immunity in cancer patients and in preclinical models.

Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us

Retrieved on: 
Thursday, March 25, 2021
Medicine, Medical specialties, Vaccination, Clinical medicine, Medical research, Cancer vaccines, Vaccines, Vaccine, Virology, COVID-19 vaccine, Therapeutic vaccines, Cancer vaccine

Amid the attention given to COVID vaccines, new vaccines that target different types of cancers are gaining momentum.

Key Points: 
  • Amid the attention given to COVID vaccines, new vaccines that target different types of cancers are gaining momentum.
  • A new ovarian cancer 'therapeutic' vaccine from Canadian company BioVaxys Technology Corp. (OTCPK: LMNGF) (CSE: BIOV) is making headlines in the UK .
  • It's termed 'therapeutic' because it can be used as a treatment for those who are already ill.
  • Merck recently decided to scrap its COVID-19 vaccine candidates, after two shots generated comparatively weak immune responses in early-stage studies.

Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us

Retrieved on: 
Thursday, March 25, 2021
Medicine, Medical specialties, Vaccination, Clinical medicine, Medical research, Cancer vaccines, Vaccines, Vaccine, Virology, COVID-19 vaccine, Therapeutic vaccines, Cancer vaccine

Amid the attention given to COVID vaccines, new vaccines that target different types of cancers are gaining momentum.

Key Points: 
  • Amid the attention given to COVID vaccines, new vaccines that target different types of cancers are gaining momentum.
  • A new ovarian cancer 'therapeutic' vaccine from Canadian company BioVaxys Technology Corp. (OTCPK: LMNGF) (CSE: BIOV) is making headlines in the UK .
  • It's termed 'therapeutic' because it can be used as a treatment for those who are already ill.
  • Merck recently decided to scrap its COVID-19 vaccine candidates, after two shots generated comparatively weak immune responses in early-stage studies.

Merck Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving Therapies

Retrieved on: 
Wednesday, March 17, 2021
Medical specialties, Medicine, Health sciences, Vaccination, Virology, Medical research, Vaccine, COVID-19 vaccine, Cancer vaccines, COVID-19 vaccines, Merck & Co.

With the 25million investment, the company is accelerating its European expansion plans for this key technology, which is used for the production of Covid-19 vaccines and other lifesaving therapies.

Key Points: 
  • With the 25million investment, the company is accelerating its European expansion plans for this key technology, which is used for the production of Covid-19 vaccines and other lifesaving therapies.
  • Our new European production unit will increase capacity of the urgently needed supply of single-use assemblies to vaccine and therapeutic manufacturers worldwide.
  • At the latter site, Merck is currently working to double the local single-use production capacity by the end of 2021.
  • All Merck news release are distributed by email at the same time they become available on the Merck Website.

Global Cancer Peptide Therapeutics Drug Market Size Clinical Trials Insight 2026

Retrieved on: 
Wednesday, March 10, 2021
Clinical medicine, Medicine, Medical specialties, Cancer, Immunotherapy, Cancer vaccines, Vaccine, Tumor antigen vaccine

NEW DELHI, March 10, 2021 /PRNewswire/ -- "Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026" Report highlights:

Key Points: 
  • NEW DELHI, March 10, 2021 /PRNewswire/ -- "Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026" Report highlights:
    Global cancer Peptide Market Opportunity: > US$ 20 Billion By 2026
    Global Peptide Cancer Therapeutics Clinical Trials Overview by Company, Country, Indication, Phase & Formulation
    Cancer and its available treatments had been facing a huge debate regarding the efficacy as well as efficiency against specific cancer types but since the arrival of cancer immunotherapy and all the available therapies under it, the debates questioning the cancer market has come to an end.
  • Among all the therapies, the one that has been considered as a backbone for the overall progress of the cancer immunotherapy is cancer peptide vaccination.
  • Cancer peptide vaccination holds a strong potential towards treating solid tumors because the protocols that it is associated with it holds a strong clinical research platform.
  • The introduction of peptide vaccines into the cancer development has made a huge impact on the overall cancer therapeutics market.

Global Cancer Peptide Therapeutics Drug Market Size Clinical Trials Insight 2026

Retrieved on: 
Wednesday, March 10, 2021
Clinical medicine, Medicine, Medical specialties, Cancer, Immunotherapy, Cancer vaccines, Peptide vaccine, Vaccine, Gustav Gaudernack

Kuick Research Report Gives Insight on Oncology Peptide Market Sales Size, Clinical Trials, Commercial Opportunity ,Other Clinical & Commercial Parameters Associated With Global Cancer Peptide Market

Key Points: 
  • Kuick Research Report Gives Insight on Oncology Peptide Market Sales Size, Clinical Trials, Commercial Opportunity ,Other Clinical & Commercial Parameters Associated With Global Cancer Peptide Market
    NEW DELHI, March 10, 2021 /PRNewswire/ -- "Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026" Report highlights:
    Global cancer Peptide Market Opportunity: > US$ 20 Billion By 2026
    Global Peptide Cancer Therapeutics Clinical Trials Overview by Company, Country, Indication, Phase & Formulation
    Cancer and its available treatments had been facing a huge debate regarding the efficacy as well as efficiency against specific cancer types but since the arrival of cancer immunotherapy and all the available therapies under it, the debates questioning the cancer market has come to an end.
  • Among all the therapies, the one that has been considered as a backbone for the overall progress of the cancer immunotherapy is cancer peptide vaccination.
  • Cancer peptide vaccination holds a strong potential towards treating solid tumors because the protocols that it is associated with it holds a strong clinical research platform.
  • The introduction of peptide vaccines into the cancer development has made a huge impact on the overall cancer therapeutics market.

St. Jude launches program to boost HPV cancer prevention across the globe

Retrieved on: 
Friday, March 5, 2021
Cancer, Infectious causes of cancer, Vaccination, Clinical medicine, Papillomavirus, Gynaecological cancer, Heather Brandt, Cancer vaccines, Vaccines, HPV vaccine, Human papillomavirus infection, Cancer prevention

"HPV vaccination can have major impact on public health, as we could eliminate most cancers caused by HPVbut people have to get vaccinated."

Key Points: 
  • "HPV vaccination can have major impact on public health, as we could eliminate most cancers caused by HPVbut people have to get vaccinated."
  • Of those millions, more than 36,000 will be diagnosed with an HPV-related cancer every year.
  • The St. Jude HPV Cancer Prevention Program is led by Heather Brandt, Ph.D., a social and behavioral scientist with expertise in cancer prevention and control.
  • In addition to her role as director, she serves as the co-associate director of outreach for the St. Jude Comprehensive Cancer Centerand works closely with members of the St. Jude Epidemiology and Cancer Control Department.